ALX Oncology Holdings, Inc. (ALXO)
1.17
-0.02
(-1.68%)
USD |
NASDAQ |
Oct 23, 16:00
1.17
0.00 (0.00%)
After-Hours: 20:00
ALX Oncology Holdings Enterprise Value : 34.52M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 34.52M |
| October 22, 2026 | 37.29M |
| October 21, 2026 | 31.76M |
| October 20, 2026 | 44.20M |
| October 19, 2026 | 30.38M |
| October 16, 2026 | 19.32M |
| October 15, 2026 | 11.03M |
| October 14, 2026 | -3.529M |
| October 13, 2026 | 8.206M |
| October 12, 2026 | 46.96M |
| October 09, 2026 | 45.58M |
| October 08, 2026 | 35.90M |
| October 07, 2026 | 28.99M |
| October 06, 2026 | 26.23M |
| October 05, 2026 | 40.05M |
| October 02, 2026 | 41.43M |
| October 01, 2026 | 52.49M |
| September 30, 2026 | 64.93M |
| September 29, 2026 | 59.40M |
| September 28, 2026 | 64.93M |
| September 25, 2026 | 53.87M |
| September 24, 2026 | 60.09M |
| September 23, 2026 | 75.99M |
| September 22, 2026 | 93.95M |
| September 21, 2026 | 102.25M |
| Date | Value |
|---|---|
| September 18, 2026 | 107.78M |
| September 17, 2026 | 113.31M |
| September 16, 2026 | 116.07M |
| September 15, 2026 | 134.04M |
| September 14, 2026 | 138.88M |
| September 11, 2026 | 140.95M |
| September 10, 2026 | 135.42M |
| September 09, 2026 | 127.13M |
| September 08, 2026 | 149.24M |
| September 04, 2026 | 150.62M |
| September 03, 2026 | 153.39M |
| September 02, 2026 | 160.30M |
| September 01, 2026 | 146.48M |
| August 31, 2026 | 139.57M |
| August 28, 2026 | 149.24M |
| August 27, 2026 | 156.15M |
| August 26, 2026 | 146.48M |
| August 25, 2026 | 149.24M |
| August 24, 2026 | 147.86M |
| August 21, 2026 | 154.77M |
| August 20, 2026 | 147.86M |
| August 19, 2026 | 157.53M |
| August 18, 2026 | 160.30M |
| August 17, 2026 | 145.09M |
| August 14, 2026 | 143.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.97M |
| Total Expenses (Quarterly) | 17.97M |
| EPS Diluted (Quarterly) | -0.1325 |
| Earnings Yield | -97.27% |
| Normalized Earnings Yield | -96.98 |